Loading
companiesCompany
Suzhou Zelgen Biopharmaceuticals
Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.
Also called: Zelgen泽璟制药
Overview
Suzhou Zelgen Biopharmaceuticals, based in Suzhou, founded in 2009 and listed as 688266.SS, developed donafenib, the deuterated version of sorafenib that beat the original in first-line liver cancer and was approved in China in 2021. Donafenib, sold as Zepsun, was approved in 2021 for hepatocellular carcinoma and in 2022 for thyroid cancer on the strength of the ZGDH3 trial against sorafenib; the pipeline includes jaktinib, a JAK inhibitor for myelofibrosis, and recombinant human thrombin, and the company was among the first listed on Shanghai's STAR Market before reaching profitability. OnCo links it to donafenib and to ZGDH3. Whether a deuterated improvement on an older drug can hold its place as immunotherapy combinations take over first-line liver cancer is the open question. Donafenib has its own page.
Headquarters
Suzhou, CN
Scorecard
All companies#166of 1244 companies, score 35
- approved products +6
- phase 3 +3
- phase 1/2 +1
- targets +4
- modalities +4
- regions +1
- registry trials +16
1 approved, 1 in phase 3, 1 earlier, 2 targets, 66 registry studies. Formula on the scorecards page.
Type
Biotech · 688266.SS
Stage
Public
Website
Founded
2009
ApprovedSmall-molecule multi-kinase inhibitor (deuterated sorafenib)
Donafenib · Zepsun
Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.
Phase 3trispecific T-cell engager antibody (DLL3 x DLL3 x CD3, per the sponsor's pipeline page; form not stated in the registry record)
ZG006 is an experimental investigational agent whose form is not stated in the registry from Suzhou Zelgen Biopharmaceuticals in phase 3 trials for non-small-cell lung cancer and neuroendocrine tumours, with its target not yet stated publicly.
Phase 2Oral kinase inhibitor
Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.
Similar pages
- PersonShukui Qin
Shares ZGDH3 (donafenib vs sorafenib), Donafenib and the tag china.
- TreatmentSintilimab
Shares Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma and the tag china.
- TreatmentThyrotropin alfa
Shares Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal, rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC).
- Key paperSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Shares ZGDH3 (donafenib vs sorafenib), Donafenib.
fronts
drugs
ApprovedSmall-molecule multi-kinase inhibitor (deuterated sorafenib)
Donafenib · Zepsun
Phase 2Oral kinase inhibitor
Phase 3trispecific T-cell engager antibody (DLL3 x DLL3 x CD3, per the sponsor's pipeline page; form not stated in the registry record)
trials
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone WithdrawalDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in PDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung CancerStudy of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerStudy of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerStudy of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory LymphomaStudy of ZG005 in Patients With Advanced Solid TumorsStudy of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid TumorsStudy of ZGGS18 in Patients With Advanced Solid TumorsStudy of ZGGS34 in Participants With Advanced Solid TumorsZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaZGDH3 (donafenib vs sorafenib)